# GRI Bio, Inc.

GRI Bio, Inc. is a public company listed on Nasdaq as GRI, headquartered in La Jolla, CA, United States.

## Company overview

- **Legal name:** GRI Bio, Inc.
- **Former names in filing history:** Vallon Pharmaceuticals, Inc. (2020-09-11 to 2023-04-21)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** La Jolla, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: GRI
- **SEC CIK:** 0001824293

## About

GRI Bio, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001824293, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-01-30, it reported net income of USD -11,956,000; total assets of USD 8,666,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Net income:** -$12.0M (USD -11,956,000)
- **Total assets:** $8.7M (USD 8,666,000)
- **Cash and equivalents:** $8.2M (USD 8,229,000)
- **Operating cash flow:** -$10.2M (USD -10,186,000)

### FY2024 (period ended 2024-12-31)

- **Net income:** -$8.2M (USD -8,207,000)
- **Total assets:** $5.7M (USD 5,739,000)
- **Cash and equivalents:** $5.0M (USD 5,028,000)
- **Operating cash flow:** -$8.6M (USD -8,611,000)

### FY2023 (period ended 2023-12-31)

- **Net income:** -$13.0M (USD -13,037,000)
- **Total assets:** $3.0M (USD 2,956,000)
- **Cash and equivalents:** $1.8M (USD 1,808,000)
- **Operating cash flow:** -$9.0M (USD -8,990,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$7.0M (USD -7,024,000)
- **Total assets:** $4.2M (USD 4,152,000)
- **Cash and equivalents:** $3.8M (USD 3,781,000)
- **Operating cash flow:** -$7.1M (USD -7,135,000)
- **Later filings:** Net income, Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form DEF 14A — filed 2026-09-28 — period 2026-11-04 — DEF 14A
- Form 8-K — filed 2026-09-08 — period 2026-09-08 — 8-K
- Form 10-Q — filed 2026-08-14 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-06-18 — period 2026-06-18 — 8-K
- Form 8-K — filed 2026-05-14 — period 2026-05-14 — 8-K
- Form 10-Q — filed 2026-05-13 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-02-04 — period 2026-02-04 — 8-K
- Form 10-K — filed 2026-01-30 — period 2025-12-31 — 10-K
- Form 8-K — filed 2026-01-30 — period 2026-01-29 — 8-K
- Form 8-K — filed 2026-01-28 — period 2026-01-28 — 8-K
- Form 8-K — filed 2026-01-21 — period 2026-01-21 — 8-K
- Form 8-K — filed 2026-01-16 — period 2026-01-15 — 8-K

---

Updated: 2026-10-23T06:09:42Z

Canonical page: https://altss.com/profile/gri-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology